Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Clinical trial NCT03086395 · WITHDRAWN
Trial details
- NCT number
- NCT03086395
- Sponsor
- Case Comprehensive Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-01
- Primary completion
- 2018-01-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.